Biotech at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

51 biotech are at CTAD 2026 — 62 presentations on the program. Most represented: Alzheon (2 on the program), Annovis Bio (2 on the program), AriBio (2 on the program). 20 of them have their own page in this guide. As of Oct 8, 2026.

All 315 organizations at CTAD 2026 →

Showing 1–15 of 51 organizations

Organization	CTAD 2026 Attendance
Alzheon Framingham, Massachusetts
alzheon.com Biotech Develops valiltramiprosate (ALZ-801), an oral anti-amyloid drug tested in APOE4/4 carriers with early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/Aβ42 Ratio in APOE4/4 Homozygotes and their Correlations to Clincial and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD (P011) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial (P012) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Effects of Valiltramiprosate on Plasma P-tau217 and Select Pro-Inflammatory and Vascular Injury Biomarkers with the NULISA CNS Panel: Exploratory Analyses from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD (P013) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers
Annovis Bio Malvern, Pennsylvania
annovisbio.com Biotech Develops buntanetap, an oral small molecule that lowers production of neurotoxic proteins, in a pivotal trial in early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients (P025) Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Predicting blood–brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer’s disease using artificial intelligence (P121) Digital assessment and AI Talk Thu Nov 19 3:52pm Restoring Proteostasis in Alzheimer’s Disease with Buntanetap, a Small-Molecule Translational Inhibitor of Neurotoxic Proteins Other mechanisms and targets
AriBio Seongnam, South Korea
aribiogroup.com Biotech Korean biotech developing AR1001 (mirodenafil), an oral PDE5 inhibitor, in the Phase 3 POLARIS-AD trial in early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer’s Disease Trial (P135) Digital assessment and AI · Trial design and endpoints Poster AriBio: Building an Oral Therapeutic Franchise Across Alzheimer’s Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005 (P515) Other mechanisms and targets
MODAG Wendelsheim, Germany
modag.net Biotech German biotech developing small molecules and PET tracers that target toxic alpha-synuclein aggregates in neurodegenerative diseases.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Safety, tolerability, pharmacokinetics and changes in CSF α-synuclein seeding activity and the CSF proteome in a first-in-patient trial of the oligomer modulator anle138b (P046) Other mechanisms and targets · Blood and CSF biomarkers Talk Thu Nov 19 3:05pm [¹⁸F]MODAG-009 PET imaging of alpha-synuclein pathology in the presence of amyloid-beta and tau co-pathology across the AD-DLB spectrum PET and MRI imaging
Nuuron Berlin, Germany
nuuron.com Biotech Berlin company developing non-invasive ultra-high-frequency visual stimulation to improve episodic memory in Alzheimer's disease.	Poster Wed Nov 18 7:15am–5:30pm Primary endpoint evaluation of ultra-high frequency visual stimulation intervention on episodic memory impairment in Alzheimer’s disease (P188) Other mechanisms and targets Poster The “Memory Pacemaker”: A non-invasive brain stimulation to improve episodic memory using ultra-high-frequency visual stimulation (P518) Other mechanisms and targets
Priavoid Düsseldorf, Germany
priavoid.com Biotech Develops oral all-D-peptide drugs that break up toxic protein aggregates; lead candidate PRI-002 is in phase 2 for Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The unique mode of action of the orally applied PRI-002 and its confirmed target engagement in the phase 2b study PRImus-AD (P017) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PRImus-AD: Design, Recruitment and Baseline Data of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002 (P021) Anti-amyloid and anti-tau therapies
P PRInnovation Düsseldorf, Germany
Biotech Company set up by Germany's federal innovation agency SPRIND to sponsor the PRImus-AD phase 2 trial of Priavoid's oral drug PRI-002.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PRImus-AD: Biomarker Profile Data of the phase 2b study treating early AD patients with the novel drug candidate PRI-002 (P018) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PRImus-AD: Safety data of the Phase 2b study treating early AD patients with the novel drug candidate PRI-002 (P020) Anti-amyloid and anti-tau therapies
REGEnLIFE Paris, France
regenlife.com Biotech Makes the RGn, a photobiomodulation device worn on the head and abdomen, tested in the Light4Life pivotal trial in Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Brain–Gut Photobiomodulation in Mild-to-Moderate Alzheimer’s Disease: Progress Update from the Light4Life Pivotal Trial (P030) Other mechanisms and targets Poster Advancing Brain–Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer’s Disease (P521) Other mechanisms and targets
Suven Life Sciences Hyderabad, India
suven.com Biotech Indian drug developer running a phase 3 trial of masupirdine, a 5-HT6 antagonist, for agitation in Alzheimer's dementia.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer’s type (P033) Neuropsychiatric symptoms Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects (P066) Other mechanisms and targets
Acumen Pharmaceuticals Newton, Massachusetts	◇Silver Sponsor
acumenpharm.com BiotechSilver Sponsor Develops sabirnetug, an antibody targeting toxic amyloid-beta oligomers, tested in the Phase 2 ALTITUDE-AD trial in early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue ALTITUDE-AD: Qualitative interviews assessing treatment expectations and motivations for clinical trial participation in early Alzheimer’s disease (P023) Trial design and endpoints Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Perspectives on the care experience in early Alzheimer’s: Narratives from study partners in the ALTITUDE-AD clinical trial (P024) Trial design and endpoints
Biomed Industries San Jose, California
biomedind.com Biotech Develops NA-831, an oral drug proposed to promote neurogenesis, for Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease (P173) Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer’s Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke (P174) Other mechanisms and targets
Voyager Therapeutics Lexington, Massachusetts
voyagertherapeutics.com Biotech Develops an anti-tau antibody and blood-brain-barrier-penetrant gene therapies, including tau-lowering VY1706, for Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Baseline Characteristics of Participants Enrolled in a Multiple Ascending Dose Study of the C-Terminal Targeting Anti-Tau Antibody VY7523 in Early Alzheimer’s Disease (P054) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue First-in-Human Study Design of VY1706, a Systemically Administered Blood-Brain Barrier (BBB)-Penetrant Tau Lowering Gene Therapy in Early Alzheimer’s Disease (P055) Anti-amyloid and anti-tau therapies
Acadia Pharmaceuticals San Diego, California	◇Silver Sponsor
acadia.com BiotechSilver Sponsor Develops and markets neuroscience medicines, including pimavanserin (Nuplazid) for Parkinson's disease psychosis, and studies treatments for neuropsychiatric symptoms.	Poster Wed Nov 18 7:15am–5:30pm Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer’s Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217 (P303) Neuropsychiatric symptoms · Blood and CSF biomarkers
Alzheimer Project Santo Domingo, Dominican Republic	◆Gold Sponsor
alzheimerproject.com BiotechGold Sponsor AI-driven initiative that pairs computational modelling with laboratory experiments to discover Alzheimer's therapies.	Poster Solving the Alzheimer Equation (P513)
Cognito Therapeutics Cambridge, Massachusetts	◆Gold Sponsor
cognitotx.com BiotechGold Sponsor Develops Spectris, a headset delivering 40 Hz light and sound stimulation, in the Phase 3 HOPE study in Alzheimer's disease.	Poster Wed Nov 18 7:15am–5:30pm Spectris treatment is associated with a coordinated plasma proteomic response: Module-level analysis from the OVERTURE feasibility study in mild-to-moderate Alzheimer’s disease (P223) Other mechanisms and targets · Blood and CSF biomarkers

Instantly find 20 buyers from biotech

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction

Instantly find 20 buyers from biotech

Browse CTAD 2026 by